专栏名称: 生物极客
北京合生基因科技有限公司(Beijing Syngentech Co., LTD.)是一家专注于合成生物学在科研和医药健康领域应用的生物技术公司。合生基因致力于为全球生命科学研究者提供世界一流的个性化合成生物学技术服务与科研产品。
目录
相关文章推荐
生物学霸  ·  856 项,2025 ... ·  昨天  
BioArt  ·  ​Nat ... ·  3 天前  
BioArt  ·  Cell Metab | ... ·  3 天前  
生物学霸  ·  用 1 公斤 DNA ... ·  4 天前  
BioArt  ·  Nature | ... ·  6 天前  
51好读  ›  专栏  ›  生物极客

跟CNS文章学英语-替代CarT技术文章里面的那些英语

生物极客  · 公众号  · 生物  · 2017-10-09 23:37

正文

刚才这篇文章中,我们讲到了替代CarT技术,我们不妨想一想,如果这个时候,要求你去讲述这篇文章,你该如何用英语来描述各种情景:

  1. 这个双特异性抗体如何制备的?


    ERY974 was generated by combining two antibodies, specifically an anti- GPC3 antibody (clone GC33) that we previously obtained (36) and an anti-CD3 antibody (clone CE115) that was newly obtained by immu- nizing a rat with human CD3e (CD3E) recombinant protein. 

gernerated 和combine与obtain,勾勒了整个技术路线。


A common light chain was generated by complementarity-determining region and framework region (CDR/FR) shuffling as previously de- scribed 

可以看到紧随其后,事实上,作者用了类似的句型。


Screening of the assembly by binding assay identified a lead common light chain thatconfers an antibody of the strongest affinity against GPC3 or CD3Ewhen combined with the heavy chains from the respective parental anti- bodies. 

confer这个词描绘了 某某事物的功能。


This was to avoid GPC3-independent cytokine release by engaging Fcg receptors and CD3. To facilitate heterodimerization of the two heavy chains by changing the CH3 interface electrical charge (40), we introduced E356K and K439E mutations on each heavy chain. A K196Q mutation was also introduced on the heavy chain of the GPC3 arm to reduce the isoelectric point (pI) to facilitate separation of the homodimers of each heavy chain by ion chromatography during the manufacturing process  


通过描绘出相应的动词,我们可以看到灵活的使用好动词可以很好的组织语言。

另外合理的进行因果逻辑的递进很有帮助。


The resulting molecule, termed ERY974, was confirmed to specifically bind membranous hu- man GPC3 and CD3E by flow cytometry analysis using cell lines over- expressing either antigen.

最难的仍然是introduction部分的写作:

Over the past decade, extraordinary clinical benefits of cancer immu- notherapies have been demonstrated, such as durable responses even for late-stage cancers. In particular, the clinical outcomes of immune checkpoint inhibitors such as antiCTLA-4 (cytotoxic T lymphocyteassociated protein4) and antiPD-1 (programmed cell death protein1) antibodies have been impressive, and they are changing the paradigmof cancer treatment .

事实上,在introduction部分,这些介绍性的语句也有一定的规律可寻,小编争取下次给大家奉上introduction汇编。